Compare Hexindo Adiperkasa Tbk. (HEXA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hexindo Adiperkasa Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Hexindo Adiperkasa Tbk. trades at Rp4,460 (market cap 3.75T, 384.1K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Hexindo Adiperkasa Tbk. is far larger — about 35.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| HEXA | SCPI | |
|---|---|---|
Market Cap | 3.75T | 104.4B |
Volume | 384.1K | — |
Lot | 3.84K | — |
Turnover | 1.71B | — |
Average Price | 4,456.78 | — |
Value | 1.71B | — |
Indicative Equilibrium Price | 4,460 | — |
Indicative Equilibrium Volume | 107 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hexindo Adiperkasa Tbk.
PT Hexindo Adiperkasa Tbk (the Company) was established on November 28, 1988 based on notarial deed No.37 of Mohamad Ali. The deed of establishment was approved by the Ministry of Justice in its decision letter No. C2-4389.HT.01.01.TH.89 dated May 12, 1989 and was published in Supplement No. 1251 of the State Gazette No.54 dated July7, 1989. Presently, the Company acts as a distributor of certain heavy equipment and related spare parts with the trademark of Hitachi, John Deere and Ammann. The Company’s registration statement for the public offering of its 10 million shares of stocks (with Rp 1000 per value per share) at on offer price of Rp 2,800 per share become affective in accordance with the letter No.S-1958/PM/1994 dated December 5, 1994 issued by the Chairman of the Capital Market Supervisory Agency (BAPEPEAM). The excess of the proceeds over the par value of the shares of stock was recorded as “Capital paid in excess of par value”. The Company’s registration statement for the first limited public offering of 42 million shares to stockholders with pre-emptive rights (with Rp 1,000 per value per share) at an offer price of Rp 1,000 per share became effective in accordance with the letter No.S-1264/PM/1998 dated June 19, 1998 issued by the Chairman of BAPEPAM.
Read more on HEXA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
